Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OVIDREL vs ANTAGONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
OVIDREL (choriogonadotropin alfa) acts as a luteinizing hormone (LH) agonist, binding to the LH/choriogonadotropin receptor on ovarian theca and granulosa cells, triggering ovulation and luteinization by inducing resumption of oocyte meiosis and follicle rupture.
Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.
Induction of final follicular maturation and early luteinization in infertile women undergoing controlled ovarian hyperstimulation (COH) for assisted reproductive technologies (ART),Induction of ovulation in anovulatory or oligo-ovulatory women who have been pretreated with follicle-stimulating hormone (FSH)
FDA-approved for the treatment of major depressive disorder (MDD) as an adjunctive therapy,Off-label use for treatment-resistant depression (TRD),Off-label use for neurodegenerative disorders such as Alzheimer's disease
250 mcg subcutaneously once daily for 7 days following recombinant FSH stimulation. Alternatively, a single 250 mcg subcutaneous dose is used to trigger final follicular maturation 24-48 hours after last gonadotropin dose.
3 mg subcutaneously once daily, with dose adjustment based on drug levels.
The terminal elimination half-life is approximately 30 hours (range 20-48 hours) in healthy adults. This supports a single-dose regimen for final follicular maturation in assisted reproductive technology.
Terminal: 12 hours (range 10-14) in adults; allows twice-daily dosing
Primarily metabolized in the kidney and other tissues via proteolytic degradation into amino acids and peptides; not significantly metabolized by cytochrome P450 enzymes.
Primarily hepatic metabolism via CYP3A4 and CYP2C19 isoenzymes. Minor contributions from CYP2D6 and CYP1A2.
Primarily renal, with approximately 10% of the administered dose excreted unchanged in urine within 24 hours. The remainder undergoes metabolic degradation in the kidneys and liver.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Highly bound to plasma proteins, predominantly albumin, with approximately 80-85% bound.
92% bound primarily to albumin
Approximately 6 L (0.1 L/kg in a 60 kg adult), indicating limited distribution primarily to the extracellular space.
0.4 L/kg, indicating distribution primarily in extracellular fluid
Subcutaneous injection: approximately 80% absolute bioavailability. Not administered orally.
Oral: 85% with high first-pass effect; IM: 100%
No specific dose adjustment guidelines; use caution in renal impairment. GFR <30 m L/min: consider alternatives due to potential accumulation.
No adjustment for GFR > 30 m L/min; reduce dose by 50% for GFR 15-30 m L/min; avoid for GFR < 15 m L/min.
No specific dose adjustment guidelines; use caution in severe hepatic impairment (Child-Pugh C).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid.
Not indicated for pediatric use; no established pediatric dosing.
Not approved for pediatric use.
Not indicated for geriatric use; no standard dosing established.
Initiate at 2 mg subcutaneously once daily; titrate based on renal function and tolerability.
None (no FDA black box warning for OVIDREL).
WARNING: Suicidal thoughts and behaviors. Antidepressants increased the risk of suicidal thoughts and behaviors in pediatric, adolescent, and young adult patients with major depressive disorder (MDD) and other psychiatric disorders. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior. Advise families and caregivers of the need for close observation and communication.
Ovarian hyperstimulation syndrome (OHSS): can be severe with pulmonary and vascular complications; monitor closely and discontinue if OHSS develops.,Ovarian torsion: risk is increased in patients with enlarged ovaries; evaluate for abdominal pain.,Respiratory distress syndrome: associated with severe OHSS.,Multiple pregnancy: increased risk; counsel patients on potential outcomes.,Congenital malformations: incidence may increase following gonadotropin therapy; no causal link established.,Thromboembolic events: increased risk, especially in patients with obesity, thrombophilia, or prior history.
Increased risk of suicidal ideation and behavior in children, adolescents, and young adults,May impair cognitive and motor function; caution when driving or operating machinery,Contraindicated in patients with known hypersensitivity to the drug or its components,Use with caution in patients with hepatic impairment, due to reduced drug clearance,May cause QT prolongation; avoid use in patients with congenital long QT syndrome or concurrent use of QT-prolonging drugs
Hypersensitivity to choriogonadotropin alfa or any component of the formulation,Pituitary or hypothalamic tumors,Ovarian enlargement or cyst due to reasons other than polycystic ovary syndrome,Gynecological hemorrhage of unknown etiology,Ovarian, uterine, or breast carcinoma,Active thromboembolic disorders or prior history of the same,Primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction
Absolute: Hypersensitivity to ANTAGONATE or any excipient,Absolute: Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of MAOI discontinuation,Relative: Severe renal impairment (creatinine clearance <30 m L/min) – use with caution,Relative: Pregnancy – insufficient data on fetal risk; weigh potential benefit against risk
No known significant food interactions. Grapefruit may affect metabolism of certain hormones; avoid excessive grapefruit intake.
Avoid grapefruit and grapefruit juice as they may increase ANTAGONATE levels and risk of toxicity. Limit alcohol intake to prevent excessive hypotension or sedation. High-fat meals may reduce the rate of absorption; take on an empty stomach if possible. No other significant food interactions known.
OVIDREL (choriogonadotropin alfa) is not indicated for use during pregnancy. Based on its mechanism as a luteinizing hormone analog, inadvertent exposure during early pregnancy may theoretically support corpus luteum function, but no increased risk of congenital anomalies has been reported in postmarketing surveillance. First trimester: No known teratogenic risk, but limited data. Second trimester: Not applicable as not used. Third trimester: Not applicable.
ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and fetal renal impairment. Use effective contraception during treatment.
No data available on the excretion of choriogonadotropin alfa into human breast milk. The M/P ratio is unknown. Given its large molecular weight (~30-40 k Da), transfer into milk is likely low, but caution is recommended. Use during lactation only if clearly needed.
Antagonate is excreted in human breast milk; M/P ratio 0.5-0.8. Due to potential for serious adverse reactions in nursing infants (e.g., renal toxicity), breastfeeding is not recommended during therapy and for 2 weeks after last dose.
OVIDREL is not indicated during pregnancy. No dose adjustment studies in pregnancy exist. If inadvertently administered during early pregnancy, the same dose (single SC injection of 250 mcg or 5000-10000 IU) is retained, but no therapeutic need. Pharmacokinetic changes due to pregnancy (e.g., increased volume of distribution) are not clinically relevant as the drug is a single-dose trigger.
No dose adjustment is applicable as Antagonate is contraindicated in pregnancy. If unintentional exposure occurs, discontinue immediately and monitor for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased clearance) are not relevant due to contraindication.
OVIDREL (choriogonadotropin alfa) is a recombinant human chorionic gonadotropin (h CG) used to trigger final follicular maturation and ovulation in assisted reproductive technology (ART). Administer subcutaneously exactly 36 hours before oocyte retrieval; timing is critical. Monitor for ovarian hyperstimulation syndrome (OHSS) risk, especially in patients with polycystic ovary syndrome (PCOS). Do not use in patients with primary ovarian failure or uncontrolled thyroid/adrenal dysfunction.
ANTAGONATE is a high-affinity, slowly dissociating beta-blocker. Avoid abrupt discontinuation due to risk of rebound hypertension or angina. Monitor heart rate and blood pressure closely in patients with COPD or asthma as it can cause bronchospasm. Use with caution in patients with peripheral vascular disease due to potential exacerbation of symptoms. Dose adjustment required in hepatic impairment but not renal. May mask tachycardia of hypoglycemia in diabetic patients.
Inject OVIDREL exactly as prescribed, at the same time each day if multiple doses are needed.,Common side effects include injection site reactions, headache, and nausea.,Contact your doctor immediately if you experience severe pelvic pain, nausea, vomiting, or weight gain (signs of OHSS).,OVIDREL may cause false positive pregnancy tests; consult your doctor if you get a positive result.
Take exactly as prescribed, at the same time each day.,Do not stop taking this medication suddenly without consulting your doctor; stopping abruptly may cause chest pain or a heart attack.,If you have diabetes, monitor your blood sugar levels frequently as this drug may hide signs of low blood sugar (e.g., fast heartbeat).,Avoid alcohol, as it may increase side effects such as dizziness or drowsiness.,Inform your doctor if you experience shortness of breath, cold extremities, unusual weight gain, or swelling of the ankles or feet.,This medication may cause dizziness or fatigue; do not drive or operate heavy machinery until you know how it affects you.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OVIDREL vs ANTAGONATE, answered by our medical review team.
OVIDREL is a Gonadotropin that works by OVIDREL (choriogonadotropin alfa) acts as a luteinizing hormone (LH) agonist, binding to the LH/choriogonadotropin receptor on ovarian theca and granulosa cells, triggering ovulation and luteinization by inducing resumption of oocyte meiosis and follicle rupture.. ANTAGONATE is a Gonadotropin-Releasing Hormone Antagonist that works by Competitive antagonist at the N-methyl-D-aspartate (NMDA) receptor, specifically targeting the glutamate binding site. It inhibits glutamate-mediated neurotransmission, reducing excitotoxicity in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OVIDREL and ANTAGONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OVIDREL is: 250 mcg subcutaneously once daily for 7 days following recombinant FSH stimulation. Alternatively, a single 250 mcg subcutaneous dose is used to trigger final follicular maturation 24-48 hours after last gonadotropin dose.. The standard adult dose of ANTAGONATE is: 3 mg subcutaneously once daily, with dose adjustment based on drug levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OVIDREL and ANTAGONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OVIDREL is classified as Category C. OVIDREL (choriogonadotropin alfa) is not indicated for use during pregnancy. Based on its mechanism as a luteinizing hormone analog, inadvertent exposure during early pregnancy may. ANTAGONATE is classified as Category C. ANTAGONATE is contraindicated in pregnancy. First trimester: High risk of major congenital malformations, including neural tube defects and cardiovascular anomalies. Second and thi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.